Medtronic Inc., the Fridley, Minnesota-based medical device company, announced Thursday that the U.S. Food and Drug Administration approved the Attain Ability Plus and the Attain Ability Straight left-heart leads for use with cardiac resynchronization therapy (CRT) devices.
The two new dual-electrode leads are part of a line of advanced left-heart lead options that fit through the Attain Select II sub-selection catheter delivery system. They are able to navigate a variety of patient vein anatomies to enhance success during the CRT implant procedure.
“With the availability of Attain Ability Plus and Attain Ability Straight, I now have access to a comprehensive family of left-heart leads designed to address the needs of a range of heart failure patients and have a proven track record of successful delivery of CRT,” said Dr. George H. Crossley, with the Saint Thomas Research Institute and Saint Thomas Heart at Baptist Hospital in Nashville, Tennessee, in a statement.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Clinical studies conducted on these leads show that about 94 percent of physicians positively rated the ability to position the Attain Ability Plus lead to the desired cardiac veins, with a one-month, complication-free rate of 98.5 percent. Further, 96.8 percent of physicians positively rated the handling of the Attain Ability Straight and the ability to maneuver it to the appropriate veins, with a low lead-dislodgement rate of 3.2 percent.